Transferrin Adsorption onto PLGA Nanoparticles Governs Their Interaction with Biological Systems from Blood Circulation to Brain Cancer Cells

• DOI: 10.1007/s11095-011-0624-1
• Publication Date: 2011-12-13T18:59:13Z
• Authors: Jiang Chang; Archibald Paillard; Catherine Passirani; Marie Morille; Jean-Pierre Benoit; Didier Betbeder; Emmanuel Garcion
• Keywords: 0301 basic medicine; [SDV]Life Sciences [q-bio]; Chemistry, Pharmaceutical; Drug Compounding; Caveolae; Capillary Permeability; Mice; 03 medical and health sciences; Cell Line, Tumor; Animals; Lactic Acid; Drug Carriers; Brain Neoplasms; Macrophages; Glioma; Clathrin; Endocytosis; 3. Good health; [SDV] Life Sciences [q-bio]; Blood-Brain Barrier; Astrocytes; Injections, Intravenous; Female; Adsorption; Half-Life

Nanomedicines represent an alternative for the treatment of aggressive glioblastoma tumors. Behaviour of PLGA-nanoparticles (NPs) was here investigated as a function of their protein adsorption characteristics at the different biological interfaces they are expected to face in order to reach brain cancer cells.NPs were studied for size, zeta potential, blood half-life, in vitro endocytic behavior and in vivo accumulation within healthy rat brain and brain tumors.While slightly modifying size (80 to 90 nm) and zeta potential (-44 to -32 mV) protein coating of PLGA-NPs by bovine serum albumin (BSA) or transferrin (Tf) greatly prolonged their blood half-life when intravenously injected in rats and mice. In contrast with THP-1 monocytes, differentiated THP-1 macrophages, F98 glioma cells and astrocytes internalized BSA- and Tf-NPs in vitro. Increase of Tf-NP uptake by F98 cells through caveolae- and clathrin-mediated pathways supports specific interaction between Tf and overexpressed Tf-receptor. Finally, in vivo targeting of healthy brain was found higher with Tf-NPs than with BSA-NPs while both NPs entered massively within brain-developed tumors.Taken together, those data evidence that Tf-NPs represent an interesting nanomedicine to deliver anticancer drugs to glioma cells through systemic or locoregional strategies at early and late tumor stages.